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Abstract
Traumatic brain injury (TBI) is a leading cause of death and disability in people younger than 45 and is a significant public
health concern. In addition to primary mechanical damage to cells and tissue, TBI involves additional molecular mechanisms
of injury, termed secondary injury, that continue to evolve over hours, days, weeks, and beyond. The trajectory of recovery
after TBI is highly unpredictable and in many cases results in chronic cognitive and behavioral changes. Acutely after TBI,
there is an unregulated release of glutamate that cannot be buffered or cleared effectively, resulting in damaging levels of
glutamate in the extracellular space. This initial loss of glutamate homeostasis may initiate additional changes in glutamate
regulation. The excitatory amino acid transporters (EAATs) are expressed on both neurons and glia and are the principal
mechanism for maintaining extracellular glutamate levels. Diffusion of glutamate outside the synapse due to impaired uptake
may lead to increased extrasynaptic glutamate signaling, secondary injury through activation of cell death pathways, and loss
of fidelity and specificity of synaptic transmission. Coordination of glutamate release and uptake is critical to regulating
synaptic strength, long-term potentiation and depression, and cognitive processes. In this review, we will discuss dysre-
gulation of extracellular glutamate and glutamate uptake in the acute stage of TBI and how failure to resolve acute
disruptions in glutamate homeostatic mechanisms may play a causal role in chronic cognitive symptoms after TBI.
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Introduction
Traumatic brain injury (TBI) is a leading cause of morbidityand mortality worldwide, resulting in an estimated 10 million
hospitalizations or deaths per year.1 Injury is most likely during
three distinct age periods: early childhood, late adolescence, and
late adulthood.2Within the United States, TBI is the primary cause of
mortality in individuals younger than 45. The majority of TBIs result
from automobile accidents, followed by falls and recreational in-
juries.2 Additionally, members of the active duty military are at el-
evated risk of TBI, with an estimated incidence of TBI among
wounded soldiers as high as 22%.3 TBI involves both primary me-
chanical damage to brain tissues as well as molecular cascades that
propagate injury into surrounding tissue, a phenomenon known
as secondary injury.4 These metabolic effects include unregulated
neurotransmitter and ion release, cell swelling, diffuse axonal injury,
free radical production and oxidative stress, mitochondrial dys-
function, inhibited ATP production, inflammation, and altered gene
transcription.4–9 These secondary events further exacerbate the ef-
fects of the primary injury, increasing blood–brain barrier damage,
edema, ischemia, and hypoxia—ultimately augmenting the cell
death process.4,8 Due to these secondary processes, TBI continues to
evolve over weeks and months, making behavioral outcomes, par-
ticularly inmild injurieswithout focal lesions, difficult to predict.10,11
Increases in extracellular glutamate play an important role in
initiating secondary injury cascades. Extracellular glutamate levels
are regulated by a family of plasmamembrane excitatory amino acid
transporters (EAATs), localized to post-synaptic neurons and as-
trocytes.12 In the initial stages of TBI, extracellular glutamate levels
increase and glutamate buffering and clearance is impaired.13 Loss
of synaptic fidelity due to increased extrasynaptic glutamate sig-
naling may mediate persistent cognitive and emotional symptoms
after TBI. Intracellular signaling in response to injury changes lo-
calization and binding efficiency of glutamate transporters and
impairs regulation of extracellular glutamate levels. Altered gluta-
mate buffering and reuptake modulate synaptic function, leading to
neuroplastic changes in learning and memory.14 Thus, if acute
deficits in regulation of extracellular glutamate persist chronically,
they may form the molecular basis for the long-term cognitive and
emotional deficits many persons afflicted with TBI exhibit.
1Biological and Biomedical Sciences Doctoral Program, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
2Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, Ohio.
3Department of Physical Medicine and Rehabilitation, University of Alabama at Birmingham, Birmingham, Alabama.
JOURNAL OF NEUROTRAUMA 34:263–272 (January 15, 2017)
ª Mary Ann Liebert, Inc.
DOI: 10.1089/neu.2015.4373
263
Animal Models of Traumatic Brain Injury
Given the high incidence of TBI, its deleterious effects, and the
inability to invasively study the progression of the injury in hu-
mans, various animal models have been developed to investigate
the pathophysiology of TBI. Because of their smaller size and cost
effectiveness, rodents are the primary animals used to model TBI.4
However, versions of these have been adapted for use in non-rodent
models, such as pig.15 These experimental models mimic various
aspects of human TBI, allowing for comparison of injury type,
location, region, and severity.16 Four primary injury models in
rodents are commonly used: fluid percussion injury (FPI), con-
trolled cortical impact (CCI), weight-drop impact acceleration
(WDIA), and blast injury.4
Fluid percussion injury
The FPI model of injury is perhaps the most widely-used and
well-characterized model of TBI.17 FPI injury is produced by
striking of a pendulum to the back of a fluid reservoir, generating a
wave of pressure through an opening in the skull onto the dural
surface that results in temporary displacement and mechanical
deformation of the brain. FPI injuries are scalable to produce mild,
moderate, or severe TBI, and by adjusting the position of the cra-
niotomy in relation to the sagittal suture, can produce midline or
lateral models of injury, with lateral positioning being the most
common.4 FPI produces both focal and diffuse injury, including
subdural hematoma, intracranial hemorrhage, brain swelling, and
axonal shearing characteristic of TBI pathology in humans.18 Ad-
ditionally, FPI reliably produces the cognitive and behavioral
deficits associated with TBI in humans.19 FPI is used due to its
reproducibility and the ease with which injury severity can be ad-
justed; however, the need for a craniotomy, the cost of the FPI
device, and a high mortality rate due to compromises in brainstem
function are limitations of the model.20
Controlled cortical impact
The CCImodel uses a pneumatic impactor device to drive a rigid
rod into the surface of the exposed brain.21 The model induces
deformation of the cortex around the injury site and generates
widespread degradation to cortical, thalamic, and hippocampal
brain regions, resulting in tissue loss, axonal shearing, and contu-
sion.21 A primary advantage of this model is the ease with which
factors such as velocity and depth of injury can be controlled.4
The extent of cortical displacement correlates with both histo-
pathological markers of neuronal dysfunction and behavioral
deficits; thus, the model can be easily adjusted to fit experimen-
tal parameters.22 CCI represents a more focal injury than other
commonly-used models, which can have implications in behav-
ioral and anatomical characterizations.20 However, the low mor-
tality rate and reproducible pathology make CCI a useful model for
biomechanical studies of TBI.4
Weight-drop impact acceleration
The WDIA model induces trauma via a free falling guided
weight striking a metal disk cemented to the rodent’s skull.23 A
scalable injury is achieved by varying the mass of the weight and
the distance that it falls.4 The impacting force generates rapid ac-
celeration of the brain within the skull, resulting in diffuse brain
injury, including petechial hemorrhage and edema in regions from
the cortex to the brainstem without fracturing the skull.16 WDIA
produces characteristic pathological features, including widespread
and bilateral axonal and neuronal damage and extensive diffuse
axonal injury, as well as similar behavioral and cognitive defects
found in FPI and CCI models.4 While cost effective and useful in
evoking diffuse axonal injury, this model has drawbacks due to the
relative variability in injury severity.20 Despite this, the WDIA
model is useful for the study of multiple concussions, an area of
increasing importance in the study of sport-related injuries.
Blast injury models
In recent combat operations, explosive blast forces, such as those
generated by an improvised explosive device, posed considerable
risk of TBI to deployed personnel.3 Even individuals who do not
experience any external injuries subsequent to an explosion can
experience TBI as a result of the forces generated by the blast.3 In
order to understand the mechanisms involved in the propagation of
the injury from an explosive force, animal models have been de-
veloped that seek to recreate the blast injury. In these models, a
shock tube and compression forces simulate non-impact blast in-
juries.3 Characteristic features of blast injury include cerebral
edema, hyperemia, and delayed vasospasm, as well as diffuse ax-
onal injury.4 Blast injuries also lead to behavioral and cognitive
deficits similar to other models of TBI.4 The largest drawback to
blast models is the difficulty in standardizing the injury procedure
and in replicability of results between research groups.24
The Tripartite Synapse and Glutamate
in the Healthy Brain
Glutamate release
Glutamate release, activity as a ligand, and reuptake involves the
coordinated action of pre- and post-synaptic neurons, as well as
astrocytes.25 Receptors, enzymes, and transporters comprise a neu-
ron–astroglia coupled systemmodulating synaptic, perisynaptic, and
extrasynaptic glutamate levels.26,27 In the pre-synaptic neuron, glu-
tamine may be converted to glutamate by glutaminase and packaged
by vesicular glutamate transporters (VGLUT1-3) for release into
the synapse.28,29 Once released, free glutamate in the extracellular
space activates post-synaptic receptors, is removed into astrocytes
by glutamate transporters, or spills over into the extrasynaptic
space. Glutamate in the synapse may occupy and activate ionotropic
(N-methyl-D-aspartate (NMDA) receptor, a-amino-3-hydroxy-
5-methyl-isoxazole propionate (AMPA), and kainate) or metabo-
tropic glutamate receptors on both neurons and astrocytes.25,30,31
Repetitive activation of excitatory synapses increases synaptic
strength, a process known as long-term potentiation (LTP).32 LTP
and the related phenomenon long-term depression (LTD) exist in
excitatory synapses in brain regions implicated in learning and
memory.32 LTP initiation requires localized increase in intracellular
calcium in the dendritic spine, typically via activation of NMDA
receptors, which gate both calcium and sodium ions.32 Magnesium
ions block the receptor channel at physiological concentrations in a
voltage-dependent manner. Partial depolarization of the cell mem-
brane, usually via activation of the AMPA receptor, extrudes these
magnesium ions. Therefore, both pre-synaptic glutamate release and
AMPA receptor-mediated post-synaptic depolarization are typically
required for NMDA receptor–mediated calcium influx.33 Various
receptor-associated proteins for both NMDA and AMPA can then
form signaling complexes within the post-synaptic density, modu-
lating content, morphology, and function, and ultimately initiating
LTP.34,35
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Neuronal and glial glutamate transporters
EAATs are the most significant means of extracellular glutamate
regulation and are expressed in neurons and glia throughout the
brain in a region- and cell-specificmanner.36,37 EAAT1 and EAAT2
are primarily localized to astroglia, while EAAT3-4 and EAAT5 are
primarily localized to neurons and the retina, respectively.36,38
EAATs mediate glutamate transport by an electrogenic exchange of
3Na+, 1H+, and 1 glutamate molecule into the cell and 1K+ ion out
of the cell, with the net inward movement of positive charges.38–40
The glial transporters are situated in perisynaptic processes facing
the synaptic cleft.41 In the prefrontal cortex, glial transporters ac-
count for the majority of synaptic glutamate reuptake.42,43 Cortical
homogenates from EAAT2-deficient mice exhibit less than 5% of
uptake activity, compared with wild-type mice,44 and additional
investigations show that EAAT2 accounts for more than 90% of the
glutamate reuptake activity in most brain regions.45
Following EAAT-mediated uptake into astrocytes or neurons,
glutamate may enter the tricarboxylic acid cycle via conversion to a-
ketoglutarate, be converted to glutamine and transported back into
the synapse, or be released into the extracellular space by a variety of
mechanisms.46 Depending on the cell type, recovered glutamate also
may contribute to lactic acid formation. Lactate production is favored
in astrocytes, while lactate breakdown is favored in neurons.47 Lactate
is efficiently shuttled from astrocytes to neurons and may be a pre-
ferred energy substrate in neuronal structures enveloped by astrocytic
processes.47 Metabolism of glutamate in the synaptic terminals is
necessary both to provide sufficient energy to sustain transmission
and to replenish transmitter pools.48 Consequently, inadequate as-
trocytic reuptake in response to neuronal activity may both increase
signaling though extrasynaptic glutamate receptors as glutamate
spills out of the synapse and/or fail to sustain neuronal energy
requirements and transmitter pools during periods of high demand.
Regulation of glutamate reuptake
The expression of EAATs is regulated on multiple levels, in-
cluding transcription, messenger RNA (mRNA) splicing, protein
synthesis, and post-translational modification.38 Receptor tyrosine
kinase (RTK) signaling appears to represent a primary starting
point for second messenger cascades, converging on the mitogen-
activated protein kinases (MAPKs) p42 and p44, and ultimately
regulating expression of EAAT2. The dual phosphorylation of p42/
p44 MAPKs at threonine-202 and tyrosine-204 increases expres-
sion levels of EAAT2 in the presence of neuron-conditioned media,
while inhibition of RTKs by the cell-permeable typhostin A23
blocks the induction of EAAT2.49 Growth factors can bypass the
RTK-p42/44 MAPK pathway and still influence the expression of
EAAT2 by directly activating transcription factors such as cAMP-
responsive element modulator, cAMP responsive element-binding
protein (CREB), and activating transcription factor 1 (ATF-1), al-
though the induction of EAAT2 via these pathways is weaker than
through RTK activation.49
Akt kinase also regulates the expression of EAAT2 by increasing
its rate of transcription.50 Transfection with a dominant-negative
AKT lentiviral vector decreased the effects of epidermal growth
factor signaling on EAAT2 expression in astrocyte cultures, while
constitutively active AKT increased EAAT2 expression, protein
levels, and transport activity in a dose- and time-dependent man-
ner.50 Growth factor activation of PI-3K can activate not only Akt,
but also increases phosphorylation of p42/44 MAPKs, suggesting a
converging network regulating EAAT2 expression.51 Thus, in-
creased activity of a number of intracellular signaling pathways
regulate EAAT2 expression, with RTK signaling cascades, p42/44
MAP kinases, and AKT protein kinase representing key mediators
promoting EAAT2 expression.
Glutamate uptake also may be regulated through either seques-
tration of transporters into intracellular storage sites or by ubiquitin-
mediated degradation of transporters. Of primary importance in
selective EAAT downregulation is the activity of protein kinase C
(PKC). PKC has differential effects on the EAAT subtypes; in mixed
neuronal and astrocyte cultures, activation of PKC rapidly (within
minutes) decreased cell-surface expression of EAAT252 and in-
creased surface expression of the neuronal transporter EAAT3.53
These differential effects are thought to represent a switching
mechanism from astrocytic to neuronal glutamate uptake. However,
as astrocyte transport represents the primary uptake mechanism, the
overall effect in a mixed-cell culture would be reduced reuptake and
elevated extracellular levels of glutamate.53 The deletion of amino
acids 475–517 on EAAT2 abolishes the effects of PKC-induced
internalization, indicating a carboxyl-terminal phosphorylation site
on the transporter.52 This decrease in cell-surface expression did not
correspond with a reduction in total cellular levels of EAAT2, sug-
gesting the immediate effect of phorbol ester activation of PKC
involves internalization of the transporter to an intracellular se-
questration site.53 Internalization can be blocked in astrocyte cultures
expressing a dominant-negative variant of clathrin54 or by inhibition
of the ubiquitin enzymeE1,55 demonstrating an ubiquitin-dependent,
clathrin-mediated endocytic mechanism of sequestration.
In contrast to short-term activation of PKC, long-term exposure
to phorbol ester was accompanied by an overall decrease in total
cellular EAAT2 expression.54 Lysosomal inhibitors attenuate this
decrease in EAAT2 protein, suggesting a cellular mechanism by
which PKC modulates EAAT2 levels under physiological or
pathological conditions.54 In summary, astrocytic and neuronal
kinase signaling mechanisms may positively or negatively regulate
EAAT expression and transport activity through transcriptional
control or regulation of cell surface expression in a time- and
concentration-dependent manner.
Extrasynaptic glutamate signaling
Removal of glutamate from the synaptic cleft involves: 1) the
high affinity binding of glutamate by perisynaptic transporters (e.g.,
EAAT2) and 2) the transport of bound glutamate by the transporter
across the plasma membrane.41,56 Once bound, glutamate may be
‘‘unbound’’ or released instead of transported across the plasma
membrane.41,56 The relatively low rate of transport of bound glu-
tamate relative to its binding affinity suggests that the EAATs first
act as buffers for released glutamate.41 Thus, glutamate molecules
may bounce from one transporter-binding site to another until
transported, thereby limiting glutamate spillover from the synaptic
cleft into extrasynaptic areas.
Glutamate levels in the extracellular milieu are tightly regulated,
as activation of extrasynaptic glutamate receptors has potent effects.
LTP and LTD can be readily induced in the adult cortex by acti-
vation of extrasynaptic GluN2B-containing NMDA receptors.57,58
While several regions have well characterized glutamate spillover
between excitatory synapses, such as the cerebellum and hippo-
campus, there is ongoing debate regarding the extent of glutamate
diffusion in other regions, including the frontal cortex, where
spillover of glutamate may detrimentally lead to loss of input
specificity and activation of cell death pathways.59–65 Mathematical
models suggest that glutamate may diffuse and activate NMDA
receptors within a radius of 0.5lm from the release point.27 Thus,
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the spatial arrangement of glutamate synapses, their glutamate
transporter buffering zones, and extrasynaptic glutamate receptors
will determine the extent and effect of glutamate spillover.66,67
Glutamate in Acute TBI
Neurotoxicity
Elevated extracellular glutamate levels, such as through appli-
cation of exogenous glutamate and related analogues into nervous
tissue, are extremely toxic to cells.68,69 In humans, severe TBI
results in elevated cerebrospinal fluid glutamate that may persist in
some brain structures for days or perhaps weeks.70,71 Following
severe TBI in rats, microdialysis determination of extracellular
glutamate levels found a 9-fold increase over non-injured control
rats.72 High levels of glutamate deplete ATP stores due to over-
stimulation and the energy expenditure involved in reuptake.68 TBI
also transiently increases extracellular potassium levels by 6-fold
above baseline.7 The effects of increased extracellular glutamate
and potassium on ionic homeostasis and ATP expenditure are ex-
acerbated by changes in astrocytic potassium conductance fol-
lowing TBI.73 Resting astrocytes are able to effectively remove
glutamate from the synapse due to their high potassium conduc-
tance and a negatively charged resting membrane potential main-
tained in part by the inwardly rectifying potassium channel
KIR4.1.74 Conditional knockout of the KIR4.1 result in cells with a
diminished capacity to transport glutamate.75,76 KIR4.1 is not well
studied after TBI; however, it was downregulated along with GLT-
1 (EAAT2) from 4 h to at least 72 h after CCI in mice.77 The central
role of potassium channels in the fidelity of glutamate transport
highlights the importance of sodium/potassium gradient, as well as
ATP production in recovery from TBI.
Increases in extracellular glutamate in TBI also disrupt ionic
homeostasis of sodium and calcium. Supra-physiological activa-
tion of glutamate receptors increases intracellular levels of sodium
ions and leads to swelling of cells from osmotic pressure.78 Other
pathologic effects of increased extracellular glutamate involve the
actions of the neurotransmitter on ionotropic glutamate receptors
that are calcium channels.7,79 Calcium is a critical signaling mol-
ecule governing myriad cellular processes and as such is tightly
regulated with intracellular concentrations maintained around
100 nM.79 Prolonged increases in intracellular calcium disrupt
mitochondrial production of ATP and activate proteases and ki-
nases, including nitric oxide synthase. Increased activity of these
enzymes may generate reactive oxygen species, disrupt cytoskel-
etal architecture, and increase transcription of genes associated
with apoptosis pathways.79 Thus, the pathological results of in-
creased extracellular glutamate are mediated in part by increases in
intracellular levels of sodium and calcium, leading to cell swelling
and the activation of deleterious signaling pathways, respectively.
In the absence of calcium, glutamate-mediated increases in in-
tracellular sodium can lead to pathological cell swelling and cell
death in hippocampal cultures.80 However, changes in intracellular
sodium and calcium ions have disparate effects on mixed cortical
cultures. In an extracellular environment with physiological con-
centrations of both sodium and calcium, neurons exhibited imme-
diate morphological changes followed later by significant cell
degradation and death. Removal of both ions from the extracellular
environment was protective to the cells, even with prolonged glu-
tamate exposure. However, ion substitution studies (cell cultures
with extracellular environments lacking one of the two ions) sug-
gested unique roles for each of these ions in the excitotoxic cascade.
Mixed-cell cultures in a calcium-freemedia exhibitedmorphological
changes, including increased swelling and granulation, but were
largely spared from cell death and returned to previous size within an
hour.81 Cultures in media where choline was substituted for sodium
showed markedly less swelling and other morphological changes
when exposed to toxic glutamate levels, but exhibited roughly the
same amount of cell death as cultures with both ions at physiological
levels.81 These results indicate that the acute excitotoxic event pre-
cipitated by sodium appears to be transient and largely non-toxic to
cortical cells, while the glutamate induced changes in calcium ion
concentrations play a key role in subsequent cell death by over-
whelming the calcium regulatory mechanisms and activating
downstream signaling pathways.5 Thus, in clinical TBI, it is likely
that the calcium-regulated mechanisms responsible for cell death are
overwhelmed and contribute to widespread neuronal cell death.
Pathophysiological activation of downstream signaling pathways
depends on changes in calcium levels, calcium’s route of entry into
the cell, and the location of its release from intracellular storage.5 Of
particular importance for glutamate mediated neurotoxicity is the
ionotropic NMDA receptor. Studies examining calcium’s level and
route of entry into the cell found that absolute levels of intracellular
free calcium roughly corresponded with neuronal survival, but
survival was better predicted by the route of calcium entry and
duration of calcium loading.82 Neuronal cell cultures were likely to
survive excessive intracellular calcium levels when entry occurred
through voltage-sensitive channels triggered by cell depolarization;
however, similar levels produced by prolonged ligand-gated (glu-
tamate) activity resulted in significantly more cell death.82 These
effects seem to be restricted to glutamate’s activity on NMDA re-
ceptors, as increases in calcium stimulated by glutamate from non-
NMDA receptors did not have the same impact on cell survival.82
The neurotoxic effects of glutamate-evoked calcium influx are
likely due to activity of the NMDA receptor signaling pathways that
promote cellular degeneration.82
Transporters in acute TBI
Antisense oligonucleotide knockdown of EAATs show they are
critical for maintaining glutamate below toxic levels. EAAT2 knock-
down significantly increased hippocampal cell death, compared with
controls, after TBI.83Knockout of eitherGLAST (EAAT1) or GLT-1
in mice yields excitotoxic levels of glutamate similar to those ex-
perienced following TBI.84 These studies demonstrate the central
role of astrocytic EAATs, especially EAAT2, in the maintenance of
extracellular glutamate within physiological norms, and illustrate
how the pathology of TBI can be exacerbated when EAAT function
or expression is compromised. Studies in astrocyte cultures suggest
that the half-life of EAAT2 is longer than 24 h85; thus decreases in
EAAT2 expression in the hours immediately following TBI86 might
not be accounted for solely by altering transcription or translation of
the transporter. Along with degradation of EAAT2 by caspase-3,87
modulation by PKC could possibly represent a mechanism by which
the secondary injury phase of TBI induces dysfunction in glutamate
reuptake transporters and exacerbates the deleterious effects of
elevated extracellular glutamate.
Astroglial injury and/or death, caspase-mediated degradation of
glutamate transporters, reversal of sodium-calcium exchanger, and
reversal of sodium-dependent glutamate transporters are all im-
plicated in acute TBI pathology.87–89 CCI models demonstrate an
early and consistent loss of EAAT2 protein in the ipsilateral cortex
beginning 4–6 h after injury and persisting past 72 h.86 In studies
utilizing lateral FPI, EAAT2 expression in the ipsilateral cortex
may not change during the first 24 h; however, decreases in the
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ipsilateral cortex are reported at 7 days post-injury.88,90,91 More-
over, decreases may be in a specific splice variant for EAAT2,
suggesting a shift in the cellular or subcellular localization of this
transporter in TBI.91
These findings in animal models replicate analyses of human
postmortem brain in which protein levels of the astrocytic gluta-
mate transporters may be decreased.88,92 Compared with moderate
EAAT2 staining found in control patients, extensive EAAT2
staining is present in the ipsilateral cortex of TBI cases, with sur-
vival times between 1 and 24 h post-injury, indicating an increase in
EAAT2 expression in this region.92 In survival times less than 1 h
or longer than 24 h, weak and sporadic EAAT2 staining patterns
were observed. These data suggest dynamic regulation of EAAT2
expression after TBI. This transient increase in EAAT2 expression
between 1 and 24 h may represent a compensatory reaction to the
elevated extracellular glutamate levels following TBI. At longer
survival times, patients exhibit a decrease in EAAT2 expression,
possibly as a result of the activity of intracellular signaling path-
ways promoting EAAT2 degradation. It is worth noting that short-
term TBI survival is correlated with a higher injury severity93; thus,
these findings likely reflect the influence of both of these factors on
EAAT2 expression.
While astrocytic EAATs are responsible for the majority of the
removal of glutamate from the extracellular space, the neuronal
EAATs also are affected by TBI. Increases in expression of EAAT4
were found in hippocampal astrocytes 3 to 7 days following lateral
FPI.94 This finding is interesting in that EAAT4 is typically ex-
pressed in neurons.57 EAAT4 expression in hippocampal astrocytes
may represent an endogenous neuroprotective mechanism or may
be part of a phenotypic switch in reactive astrocytes.94 Other
studies have found similar instances of phenotypic switching of
typically ‘‘astrocytic’’ EAATs onto neuronal processes. For ex-
ample, hypoxia results in early loss of EAAT2 in the pig hippo-
campus, which is followed by the aberrant induction of an EAAT2
splice variant in neuronal cell types.95 Additionally, detection of an
alternately spliced variant of EAAT1 in neuronal cell cultures
following hypoxia is an early and highly sensitive marker for
neurons at risk of cell death, as normal expression of glutamate
transporters may be negatively modulated by co-expression of
these splice variants.96 Similarly, engineered expression of EAAT2
on neuronal cell types increases vulnerability to excitotoxicity in
hippocampal slice cultures.97 It is plausible that glial EAAT ex-
pression in neurons may be a compensatory attempt by the brain to
offset increases in extracellular glutamate following TBI; however,
these efforts may ultimately harm neuronal tissue by making it
more vulnerable to excitotoxicity due intracellular glutamate levels
beyond the buffering or metabolic capacity of neurons.98
Extracellular glutamate concentrations may modulate the ex-
pression of glutamate transporters. Exposure of cultured cortical
astrocytes to high levels of extracellular glutamate (20mM) de-
creased EAAT2 expression by 25 and 40% following 24 h or 72 h
exposure times, respectively.99 The decline in protein expression
was not due to astrocyte death, but corresponded to increased
glutamine synthetase protein. The decline in transporter expression
was not attenuated by non-competitive antagonists for NMDA or
AMPA receptors, supporting a receptor-independent mechanism
for decreased transporter expression.99 In summary, the acute ef-
fects of TBI on expression of glutamate transporters are mediated
by a number of paracrine and intracellular signaling factors influ-
encing the function, location, and phenotype of the transporters.
Long-term compromises in the tripartite glutamate system exac-
erbate the pathological effects of the primary injury and contribute
to the persistent deficits in cognition characteristic of the secondary
injury phase.
Glutamate in Chronic TBI
Glial dysfunction
Eight weeks following moderate lateral FPI, hippocampal cell
loss was accompanied by increased gliosis and increased GFAP
staining in the thalamus, frontal cortex, and hippocampus, indi-
cating a persistent abnormality in astrocytes.100 Additionally,
single-cell polymerase chain reaction analysis of glial acidic fi-
brillary protein (GFAP)–positive astrocytes found a dramatic shift
in gene expression 14 days after ischemic injury in populations of
reactive astrocytes.101 Reactive astrocytes have increased expres-
sion of transcripts for EAAT1, synaptosomal-associated protein 25
(SNAP25), and glutamate receptor subunits, indicating that these
cells may be starting to express ‘‘neuronal’’ genes such as SNAP25
and some of the neuronal hyperpolarization activated cyclic nu-
cleotide gated potassium channels (HCNs).101
Few studies have evaluated glutamate levels in chronic
(>14 days post-injury) animal models of TBI. A series of studies
implicated chronic dysregulation of glutamate in chronic TBI by
examining late onset behavioral morbidity as indicated by in-
creased whisker sensitivity following diffuse experimental TBI.
Over 8 weeks following moderate midline FPI, rats in both injured
and sham experimental conditions received manual whisker stim-
ulation, and behavioral responses were recorded. While sham in-
jury animals were ambivalent or soothed by whisker stimulation,
animals in the injury condition demonstrated aggravated behavioral
responses beginning at 1 week post-injury, which became signifi-
cant at 4 weeks and persisted throughout the rest of the 8 weeks.102
A follow up study examining the molecular underpinnings for this
increased whisker sensitivity supported hypersensitive glutamate
circuitry as a possible causal mechanism.103 Microelectrode array
studies found increased extracellular glutamate levels in the ventral
posterior medial hypothalamus, compared with sham-injured ani-
mals, 4 weeks following injury.103 Imaging studies after human
TBI suggest the balance of glutamate and the inhibitory transmitter
c-aminobutyric acid (GABA) may be chronically altered after
TBI.71,104,105 Thus, persistent impairments in glutamate circuitry
represent a possible mechanism for the chronic cognitive and
emotional symptoms experienced by some patients after TBI.
In addition, several studies indirectly examine the roles of gluta-
mate transporter expression, glutamate reuptake, and extracellular
glutamate in chronic FPI using novel pharmacological therapeutics.
Pharmacological blockade of sodium channels, which inhibits glu-
tamate release, attenuated GFAP immunoreactivity 2 weeks fol-
lowing moderate-to-severe lateral FPI.106 Another study found
treatment with riluzole, a pharmacological agent which inhibits so-
dium channels and decreases glutamate release, decreased cortical
lesion size 2 weeks following moderate parasagittal FPI.107 Further,
microtubule-associated protein 2 immunoreactivity 2 weeks after
moderate lateral FPI was reduced following treatment with the glu-
tamate receptor antagonist kynurenate, compared with untreated
animals.108 These studies indirectly demonstrate the role of gluta-
mate in chronic TBI by showing that inhibiting glutamate release or
modulating glutamate receptors decreases chronic pathophysiology.
Signaling in chronic TBI
Signaling events regulating glutamate neurotransmission also
are altered in chronic TBI models. Extracellular signal-regulated
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kinase (ERK) and CREB activation was decreased in hippocampal
slices following a stimulation protocol 12 weeks after parasagittal
FPI; in this same study, resting-state levels of phospho-CREB
protein were decreased in the hippocampus, suggesting persistent
signaling abnormalities.109 Interestingly, ERK and CREB are pos-
itive modulators of EAAT2 expression.49,51 Decreased activity in
this signaling pathway is consistent with diminished EAAT ex-
pression and activity. Further, ERK and CREB are molecular
markers of memory consolidation, and disruptions in these path-
ways downstream of glutamate neurotransmissionmay contribute to
the chronic cognitive difficulties observed after TBI. Using elec-
trophysiological measures, one group found increased frequency of
spontaneous inhibitory post-synaptic currents in the dentate gyrus 1
month after FPI, while another found decreased capacity for LTP in
mild, moderate, and severe TBI 8 weeks after injury.110,111 These
data suggest a mechanism for persistent alterations in the molecular
correlates of learning and memory in the chronic FPI model of TBI.
There may be a threshold level of LTP that is required to initiate
protein synthesis–dependent consolidation of memory112; thus, the
reduced capacity for LTP found 8 weeks following TBI represents a
potential mechanism for the cognitive impairment exhibited in both
human patients and animal models of TBI.
Glutamate reuptake mechanisms are closely linked to the elec-
trophysiological changes reported in chronic TBI discussed above.
In the hippocampus, baseline (i.e., ‘‘normal’’) LTP in the CA1
subfield is associated with increased glutamate reuptake; for ex-
ample, fear conditioning increased EAAT-dependent reuptake, and
blockade of EAAT3 co-localization with the NMDA receptor–
signaling complex attenuated synaptic strength.14 In a similar study
in ischemia, a disorder where glutamate excitotoxicity is believed
to play a similar role as in TBI, transient global ischemia decreased
protein expression of EAAT2 in area CA1 of the hippocampus
corresponding to decreased amplitude of glutamate evoked cur-
rents from astrocytes in this area.113 Further, reverse transcrip-
tion polymerase chain reaction demonstrated diminished EAAT2
mRNA in post-ischemic cells in hippocampal area CA1.113 These
FIG. 1. Progression of traumatic brain injury. Schematic representation of changes in glutamate release, reuptake, and activity based
on data from rodent models of traumatic brain injury. In normal brain (pre-injury), there is dense perisynaptic localization of glutamate
transporters, which shapes synaptic transmission and neuroplasticity via the buffering and removal of glutamate from the synaptic cleft.
During primary injury, several mechanisms may lead to diminished glutamate uptake, including changes in transporter expression,
signaling pathway activation, and/or proteolytic degradation of transporter protein. We posit that transporter expression and localization
is altered during secondary and chronic injury in a manner that serves to protect surviving neurons from additional injury. Finally,
consolidation of neuroplastic changes during chronic injury may include alterations in glutamate release and reuptake, contributing to
the cognitive defects found in chronic traumatic brain injury. MAPK, mitogen-activated protein kinase; K+, potassium; Na+, sodium;
JNK, c-Jun N-terminal kinase; PKA, protein kinase A; PKC, protein kinase C; PI3K-Akt, phosphoinositide 3-kinase-protein kinase B;
PSD95, post-synaptic density 95; TGFb, transforming growth factor beta; Ca2+, calcium; EAAT, excitatory amino acid transporter;
GPCR, G-protein-coupled receptor; GFAP, glial fibrillary acidic protein; NMDA, N-methyl-D-aspartic.
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results suggest that disruption in EAAT2 expression and function
contributes to astrocytic cell death in the hippocampus, and that
glutamate reuptake is important for maintaining synaptic strength
and initiating LTP in the hippocampus. Thus, impairment of glu-
tamate reuptake could account for observed electrophysiological
deficits in this region in chronic TBI.
Therapeutics addressing glutamate
Attempts to offset glutamate excitotoxicity following TBI have
largely been disappointing in clinical trials.114 Numerous therapeu-
tics agents have attempted to address the glutamate imbalance using
pre-synaptic glutamate inhibiting agents, competitive and non-
competitive NMDA receptor antagonists, cannabinoid agonists, ni-
tric oxide synthase inhibitors, AMPA antagonists, serotonin ago-
nists, and magnesium sulfates.114,115 While initially promising in
phase II clinical trials, the synthetic cannabinoid receptor agonist
dexanabinol failed to produce statistically relevant improvements in
Glasgow Outcome Score (GOS) in phase III trials.116 The compet-
itive NMDA receptor antagonist selfotel also was brought to phase
III clinical trials with similarly disappointing results. Patients in the
placebo group had statistically similar GOS scores and mortality
rates to those in the drug treatment condition and the study was
discontinued.117 Extracellular magnesium, which endogenously acts
as a non-competitive NMDA antagonist also has been investigated.
However, in moderate-to-severe TBI patients, magnesium sulfate
administration resulted in no significant improvements in survival,
seizure activity, or behavioral outcomes.118 Recent animal studies
attempting to offset the loss of glutamate homeostasis following TBI
involve the use of therapeutic drugs that upregulate glutamate
transporter expression. For example, the b-lactam antibody cef-
triaxone reversed the loss of EAAT2 expression in the ipsilateral
frontal cortex of TBI mice 7 days post-injury and resulted in lower
levels of pro-inflammatory mediators.90,119 A number of additional
compounds, including riluzole, the tricyclic antidepressant amitrip-
tyline (which upregulates EAAT expression), and the beta-carboline
alkaloid harmine (which stimulates EAAT2 activity), show promise
in multiple models of CNS injury and neurodegeneration.120
By focusing on neuronal protection, pharmacological interven-
tion may be ignoring the crucial role of astrocytes in the propaga-
tion and sustainment of the disease state. We posit that there is also
a need for glioprotective agents in therapeutic treatments of chronic
TBI. There is still much to be learned about how traumatic injury
affects EAAT expression, splice variants, trafficking, localization,
activity, and turnover that could identify new therapeutic oppor-
tunities in both acute and chronic secondary injury processes. Ac-
cumulating evidence suggests that comprehensive examination of
the glutamate reuptake mechanism and associated signal trans-
duction processes may be a high yield substrate for understanding
the pathophysiology of excitatory circuits in chronic TBI.
Conclusion
As with the proximal primary injury, alterations in glutamate
homeostasis may represent a driving event in the ongoing patho-
physiology of TBI. Failure to resolve the secondary injury may be
due in part to changes in localization and function of glutamate
transporters and their associated signaling molecules, anchoring
proteins, and metabolic pathways necessary for normal glutamate
transmission (Fig. 1). Given the strong link between proper gluta-
mate reuptake and the maintenance of synaptic strength, LTP, and
learning and memory, dysfunction in glutamate transport systems
could play a causal role in the persistent cognitive symptoms as-
sociated with chronic TBI. Prolongedmorphological andmolecular
changes in astroglia and astroglial glutamate uptake mechanisms
may be particularly important as a single astrocyte may intercon-
nect with thousands of synapses.121
Diminished glutamate reuptake capacity could have profound
effects on cognitive and behavioral outcomes associatedwith chronic
TBI. Inadequate management of glutamate in the synapse and glu-
tamate spillover into extrasynaptic domains would affect initiation,
amplitude, and sustainability of LTP and LTD, both of which are
critically important for synaptic efficiency and cognition. Insufficient
astrocytic response to neuronal activity produces electrophysiologi-
cal changes consistent with glutamate spillover from the syn-
apse.122,123 Similar mechanisms may be present in the neocortex in
schizophrenia, an illness with profound cognitive impairment.33
Taken together, these mechanismsmay explain the diffuse global
nature of cognitive and emotional symptoms experienced following
TBI; the initial injury may reset glutamate regulatory mechanisms
and molecular systems associated with cognitive performance dur-
ing the secondary injury phase. If not resolved, these changes con-
solidate, resulting in long-term alterations in glutamate homeostasis
which may diminish the ability of neurons to effectively initiate or
maintain synaptic plasticity (Fig. 1). This model suggests a thresh-
old for patient symptomology, below which a patient is asymp-
tomatic but nevertheless increasingly susceptible to developing
chronic symptoms after each subsequent injury or other CNS stress
due to incremental increases in damaged astroglia and associated
signaling deficits.
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